Streetbeat News

Regulatory

LTRN

Lantern Pharma has secured FDA clearance for its IND application for drug candidate LP-184 in solid tumors. The first-in-human Phase 1A trial is expected to launch this quarter, with completion anticipated by the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 12:32 pm

CYTH

Cyclo Therapeutics shares are trading higher after the European Patent Office allows a patent for Trappsol Cyclo, a treatment for Alzheimer's Disease.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 12:18 pm

BIIB

Biogen shares are trading lower despite the FDA's support for the company's Alzheimer's treatment, following a Friday increase in share price.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 12:07 pm

CYTH

Cyclo Therapeutics announced a notice of allowance for a European patent titled 'Methods for Treating Alzheimer's Disease.' This patent could potentially boost the company's intellectual property portfolio.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 12:07 pm

HZNP

Horizon Therapeutics announced the publication of a pivotal trial for UPLIZNA, integrating MRI and biomarker evaluation, which demonstrated accuracy and uniformity of attack diagnoses for Neuromyelitis Optica Spectrum Disorder.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 12:05 pm

MBIO

Mustang Bio announced updated data from the ongoing Phase 1/2 trial of MB-106 CAR T cell therapy, showing a favorable safety and efficacy profile in patients with Waldenstrom Macroglobulinemia, a rare form of blood cancer.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 12:03 pm

PHAT

Phathom Pharmaceuticals announced that the FDA has accepted its NDA resubmission for vonoprazan, a treatment for Erosive GERD. The FDA classified it as a Class 2 resubmission and assigned a PDUFA goal date of November 17, 2023.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 12:03 pm

VACC

Vaccitech has dosed the first patient in the PCA001 Phase 1/2 trial of VTP-850 monotherapy for prostate cancer in men with rising prostate-specific antigen after definitive local therapy.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 11:35 am

ATNM

Actinium Pharmaceuticals announced Sierra trial results for Iomab-B in treating relapsed/refractory acute myeloid leukemia at the European Hematology Association 2023 Congress. The company expects to file a BLA for Iomab-B by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 11:06 am

MRKR

Marker Therapeutics announced the treatment of the first lymphoma patient with MT-601 in a Phase 1 clinical trial. This marks a significant milestone for the company's T cell therapy program.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 11:04 am